-
Inovio Begins Clinical Trials Of Immunotherapy Cancer Treatment12/23/2014
Inovio Pharmaceuticals announced the start of their first human studies into a DNA immunotherapy both alone and in combination with another cancer therapy in development at Inovio.
-
FDA Accepts Apotex's Application For Biosimilar Cancer Drug12/23/2014
Apotex announced the FDA had accepted their application for pegfilgrastim, a biosimilar product based on Amgen’s blockbuster Neulasta,Pharmaceutical Processing(PharmPro) reports.
-
Sorrento Enters Joint Venture With NantWorks For Cancer Immunotherapies12/19/2014
Sorrento announced a collaboration with Dr. Patrick Soon-Shiong, founder of NantWorks, who has invested an initial $20 million to aid with the development of a wide range of biologic cancer and auto-immune disorder therapies addressing current unmet clinical needs.
-
Novartis Funds NIHR Trial For Sjogren's Syndrome Treatment12/12/2014
The National Institute for Health Research (NIHR) in England has announced the start of a new clinical trial to test a potential treatment for Sjogren’s Syndrome (SS).
-
Endo Acquires Testosterone Nasal Gel From Trimel Pharma12/11/2014
Endo announced that it has completed the acquisition of Nasteo, a testosterone nasal gel from Trimel Pharmaceuticals in a deal worth over $25 million. The new product joins Endo’s existing portfolio of men’s health treatments.
-
New Study: Location Limits Cancer Clinical Trial Participation12/9/2014
A new study published in the Journal of American Medical Association (JAMA) suggests that geographic location severely inhibits a cancer patient’s likelihood of participating in a clinical study, Reuters reports.
-
Indian Government Mandates Quality Accreditation For New Clinical Trials12/5/2014
The Government of India has introduced a new statute that requires all new clinical trials conducted in India to receive accreditation from a third-party Quality Council of India (QCI), reports the Economic Times (ET) of India.
-
FDA Approves Valeant's Latest Acne Treatment12/4/2014
Valeant announced that it has received FDA approval for its Onexton gel, indicated for the treatment of acne vulgaris. This approval is the latest in a series of moves that reinforces Valeant’s focus on ophthalmology and dermatology.
-
Study Finds Possible Reason for Liver Cancer Treatment Setbacks12/3/2014
Epidermal growth factor receptor (EGFR), the human protein which controls cell growth, is often mutated by cancer and found to exist in excessive numbers in cancerous cells.
-
Spreading “Right To Try” Laws Present Challenges For Pharma Industry11/25/2014
Legislatures in Arizona, Colorado, Louisiana, Michigan, and Missouri have all passed laws this year which attempt to give terminal patients faster access to experimental medicines, and there are additional initiatives starting in more states.